Recursion Pharmaceuticals (RXRX) Earnings Date & Reports
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company... Show more
RXRX is expected to report earnings to rise 7.95% to -23 cents per share on August 11
Recursion Pharmaceuticals (RXRX) Q4 2025 Earnings Recap: Revenue Surges on Milestones, Stock Jumps 12%
Key Takeaways
- Recursion reported Q4 2025 revenue of $35.5 million, beating consensus estimates of about $25 million, driven by a $30 million milestone from Roche and Genentech.
- EPS loss of $(0.21) exceeded expectations of $(0.28), improving from $(0.53) a year earlier.
- Cash and equivalents stood at $754 million, providing runway into early 2028 without additional financing.
- Phase 2 data for REC-4881 showed 75% of patients with polyp burden reduction in familial adenomatous polyposis (FAP).
- 2026 cash operating expenses (excluding partnership inflows and transaction costs) guided below $390 million.
- Shares rose 12% the day after the February 25, 2026 release.
Earnings Context and Why It Matters
Recursion Pharmaceuticals, a clinical-stage TechBio company using AI to decode biology and advance drug discovery, released its Q4 and full-year 2025 results on February 25, 2026. This report is critical for investors as it highlights progress in the company's Recursion operating system (OS), partnerships with Roche/Genentech and Sanofi, and cost management amid a challenging biotech funding environment. With five clinical programs and growing milestone payments totaling over $500 million, the results underscore Recursion's shift toward clinical validation and value creation. For shareholders, key focus areas include pipeline momentum and extended cash runway, which signal sustainability in AI-driven drug development.
For the three months ended December 31, 2025, Recursion posted revenue of $35.5 million, up sharply from $4.5 million in Q4 2024, surpassing consensus estimates of $24.6 million to $26 million. The beat stemmed from a $30 million milestone payment from Roche and Genentech, plus higher Sanofi collaboration revenue.
Net loss narrowed to $108.1 million from $178.9 million year-over-year, with EPS at $(0.21) versus expected $(0.28) and prior-year $(0.53). Research and development (R&D) expenses dipped to $95.9 million from $98.3 million, reflecting efficiency gains, while general and administrative (G&A) costs fell to $33.7 million from $77.2 million due to lower transaction expenses.
Full-year revenue reached $74.7 million, up 27% from 2024. Cash stood at $754 million, beating cost savings guidance. Pipeline highlights included positive REC-4881 Phase 2 data in FAP and REC-617 interim results in ovarian cancer. Management guided 2026 cash operating expenses below $390 million.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.
Market Reaction and Investor Sentiment
Recursion shares surged 12.3% to $3.97 on February 25, 2026, following the release, with pre-market gains reaching 16%. The positive response reflected the revenue and EPS beats, robust pipeline data, and extended cash runway. Investors interpreted the results as validation of Recursion's AI platform, boosting sentiment despite ongoing net losses typical for clinical-stage biotechs.
Forward Outlook and Key Factors to Monitor
Investors should track Recursion's pipeline milestones in 2026, including Phase 1 data for REC-1245 in the first half, FDA engagement for REC-4881, and multiple investigational new drug (IND) decisions in the second half. Upcoming readouts for REC-617 and other programs through 2027 could validate the Recursion OS further.
Partnership dynamics remain pivotal, with Sanofi having accepted five programs (totaling $134 million in payments) and Roche/Genentech advancing six Phenomaps ($213 million total). Additional option exercises or milestones could bolster revenue.
Cost discipline is key, with 2026 cash operating expenses guided under $390 million, supporting the $754 million cash position into early 2028. Broader biotech trends, such as AI integration in drug discovery and funding availability, will influence execution. The Q1 2026 earnings, expected in early May, will provide further visibility on progress.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
Industry Biotechnology